Login
$TEVA
$42.57 +$0.00 (0.0%) After hours

$TEVA SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 Form 4
12 Nov 2026 Form 4: Francis Richard D, President and CEO

Sold 250,000 shares ($10.6M)

12 Nov 2026 Form 4: Sabag Mark, See "Remarks"

Received 44,710 shares by exercise or conversion ($1.56M) · Sold 44,710 shares ($1.97M)

12 Nov 2026 Form 4: Weiss Amir, Chief Accounting Officer

Received 7,755 shares by exercise or conversion ($269K) · Sold 17,289 shares ($744K)

12 Nov 2026 Form 4
12 Nov 2026 Form 4: Brailer David J, Director

Granted 3,326 Restricted Share Units

12 Nov 2026 Form 3: Brailer David J, Director

No securities owned

12 Nov 2026 144
12 Nov 2026 144
10 Nov 2026 144
10 Nov 2026 SCHEDULE 13G/A
09 Nov 2026 144
06 Nov 2026 Form 4: Sabag Mark, See "Remarks"

Received 46,000 shares by exercise or conversion ($1.61M) · Sold 46,000 shares ($1.93M)

06 Nov 2026 Form 4: Bergwerk Dov, Interim Cheif Legal Officer

Received 26,260 shares by exercise or conversion ($861K) · Sold 26,260 shares ($1.1M)

05 Nov 2026 144
04 Nov 2026 144
03 Nov 2026 10-Q
03 Nov 2026 8-K: Results of Operations and Financial Condition

Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion

02 Nov 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support